Tag: Press Release
-
Additional Funding for PHRT Projects at PSI and Empa
Following a selection process through an international review, the PHRT Executive Committee has chosen to fund three promising projects from the ETH domain institutions, Paul Scherrer Institute (PSI) and Empa, to receive a budget envelope of CHF 1 million in total.
-
Integrated Drug Response Profiling of Myelofibrosis Patients
A recent Nature Communications paper by the Snijder & Wollscheid groups (IMSB) in collaboration with the Theocharides (USZ), Lopes (UZH), and Skoda (USB) groups, describes drugs targeting cancerous stem cells in blood of myelofibrosis patients and molecular mechanisms driving these drug responses.
-
Two Clinical Trial Projects Launched: Transforming Clinical Care with ETH Technologies
Following a highly competitive selection process by an international review panel, the PHRT Executive Committee has chosen two pioneering clinical trial projects from the ETH domain, in collaboration with clinical partners, to receive substantial funding of CHF 2 million each. These projects aim to transform the standard of clinical care by harnessing the power of…
-
Fighting Blood Cancer More Efficiently
On April 20, 2023, researchers from ETH Zurich and the University Hospitals of Zurich had a publi-cation released in Nature Cancer. Their work on multiple myeloma, a blood cancer, is enabled by Prof. Dr. Berend Snijder’s Pharmacoscopy technology, which was notably developed with funding by PHRT.
-
Pioneer Work in Spinal Cord Function Restoration
On May 24, 2023, Prof. Dr. Grégoire Courtine and his team of experts at EPFL have successfully published an article in Nature about their work on patients with spinal cord injuries, using a brain-spine interface to allow patients to walk again. The team of Prof. Courtine has received funding from PHRT.
-
Hope for patients with a severe rare disease
New research offers potential benefits for those affected by the hereditary metabolic disease methylmalonic aciduria. By combining the results of multiple molecular analyses, scientists can better diagnose this rare and severe disease. In the future, an improved understanding of the disease might also improve treatment options.
-
SPHN and PHRT organize the 2nd Joint Personalized Health Day Switzerland, “The future of data-driven medicine in Switzerland”
Bern, 24 August 2022. The Swiss Personalized Health Network (SPHN), an initiative of the State Secretariat for Education, Research and Innovation, and Personalized Health & Related Tech-nologies (PHRT), a Strategic Focus Area of the ETH Domain, have organized the 2nd Joint Per-sonalized Health Day Switzerland. With more than 200 participants from research, hospitals, politics, and…
-
ETH Board approves second phase of PHRT for 2021–2024
The ETH Board has approved a second phase of Personalized Health and Related Technologies (PHRT), one of the ETH Domain’s four strategic focus areas. PHRT will launch its next call for proposals at the beginning of 2021. Professor Bernd Wollscheid, chair of the PHRT Executive Committee, encourages ETH Domain researchers to build new competitive consortia…